Naturewise Biotech & Medicals (ROCO:4732) Research & Development: NT$138.4 Mil (TTM As of Dec. 2025)


ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
63 GF Score
Price NT$18.40
GF Value NT$22.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals Research & Development?

Naturewise Biotech & Medicals ROCO:4732 +1.66% 63 Research & Development is NT$138.4 Mil as of Dec. 2025. GuruFocus rates ROCO:4732 with a GF Score™ of 63/100 and a GF Value™ of NT$22.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Naturewise Biotech & Medicals's Research & Development for the six months ended in Dec. 2025 was NT$95.2 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$138.4 Mil.

Naturewise Biotech & Medicals  (ROCO:4732) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Naturewise Biotech & Medicals Research & Development Related Terms

Naturewise Biotech & Medicals Research & Development Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals Research & Development Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.46 49.48 30.01 72.07 138.41

Naturewise Biotech & Medicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.71 36.96 35.11 43.23 95.18
ROCO:4732
63GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$138.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$138.4 Mil mean?
Naturewise Biotech & Medicals (ROCO:4732) has a Research & Development of NT$138.4 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Research & Development too high?
Naturewise Biotech & Medicals' current Research & Development is NT$138.4 Mil. Overall, Naturewise Biotech & Medicals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Research & Development compare to VRTX and REGN?
Naturewise Biotech & Medicals' Research & Development of NT$138.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Research & Development is NT$138.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.13, compared to a current price of NT$18.40 — trading 16.9% below its estimated fair value. The current Research & Development is NT$138.4 Mil. Naturewise Biotech & Medicals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Research & Development is NT$138.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$18.40 is trading 16.9% below its estimated GF Value™ of NT$22.13. GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.

Key valuation signals for ROCO:4732:

  • Research & Development: NT$138.4 Mil
  • GF Value™: NT$22.13 vs. price of NT$18.40 (16.9% below fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
63GF Score

Get the complete analysis for ROCO:4732

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.40
Price
NT$22.13
GF Value